Pages
Products
CAG-GCaMP6f Lentivirus

CAG-GCaMP6f Lentivirus

Cat.No. :  LV00991Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00991Z
Description This lentivirus contains Ca2+ indicator GCaMP6f under the control of CAG promoter.
Target Gene GCaMP6f
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

The lentiviral vector was originally derived from the human immunodeficiency virus (HIV), which belongs to the Retroviridae family and the genus Lentivirus. It is an enveloped RNA virus. The first-generation lentiviral vector is a two-plasmid system that retains most of the components of wild-type HIV. Although it is a replication-deficient virus, the possibility of producing replication-competent HIV virus is relatively high. The second-generation lentiviral vector was changed to a three-plasmid system, which reduced the accidental recombination rate of the virus and improved safety. In addition, the original HIV-1 envelope protein was replaced with other envelope proteins, such as the glycoprotein from vesicular stomatitis virus (VSV-G), to expand the infection range of the lentivirus. Subsequent generations of lentiviral vectors have adopted continuous optimization and improvement to improve their titer and safety. The third-generation lentiviral vector removes more unnecessary viral sequences, such as auxiliary proteins vif, vpr, vpu and nef, so that the viral RNA cannot be effectively transcribed, and the probability of intentional extracorporeal recombination is lower. The fourth-generation lentiviral vector is upgraded to a four-plasmid system, and the tat sequence is removed at the same time. The probability of producing replicative viruses due to intentional extracorporeal recombination is further reduced, and safety is further improved. As a gene vector, lentivirus has the ability to transduce dividing and non-dividing cells, can perform high-efficiency gene transduction on primary cells and cell lines, can package and transduce up to 11kb of transgenes and can effectively integrate into the cell genome. Due to its wide range of infection and high transduction rate, lentivirus has become a commonly used gene delivery tool vector in the field of scientific research. In the clinical application of cell gene therapy, lentiviral vectors have become one of the main vectors for in vitro cell gene therapy. Its indications currently mainly include monogenic genetic diseases and cancer. Currently, there are hundreds of gene therapy clinical trial projects that are using lentiviral vectors to perform in vitro gene modification on cells. Among them, CAR-T drugs have become the representative of lentivirus-related gene therapy drugs, and many CAR-T drugs have been approved for marketing around the world.

In glioblastoma (GBM), the impact of an altered glycocalyx remains largely unexplored. Sialic acid, the terminal moiety of cell-coating glycans, is essential for cell-cell contacts. However, sialic acid turnover in glioma and its impact on tumor networks remain unknown. Here, visualization and quantitative analysis of newly synthesized sialic acid revealed a high incidence of de novo sialylation in GBM cells. Sialyltransferases and sialidases are highly expressed in GBM, suggesting that extensive turnover of sialic acid is associated with GBM pathology. Inhibition of sialic acid biosynthesis or desialylation affects tumor growth patterns and leads to altered network connectivity in glioblastoma cells.

Here, the researchers quantified gap junction-mediated cytosolic traffic within tumor networks by real-time imaging of fluorescence-guided cell-to-cell transfer of calcein—a fluorescent molecule that is only able to spread from cell-to-cell through intercellular gap junctions, workflow is depicted in Figure 1A. For MFA treatment, researchers observed a significant decrease in calcein receptor cells up to 150 min later (Figures 1B, C). Based on these findings of MFA-mediated functional inhibition of intercellular cytoplasmic exchange through gap junctions, calcium imaging was performed in glioblastoma cells transduced with the LV-CAG-GCaMP6f virus (Figure 1D). The researchers used 100 µM glutamate stimulation for 10 minutes to analyze network communication in tumor cells. After 5 min of recording, MFA was added, and the results showed a reduction in calcium signaling after MFA treatment (Figure 1E). Glioblastoma networks exhibited properties similar to neuronal networks, with bursts of synchronized activity, with all cells participating in network oscillations (Figure 1E).

Figure 1. Meclofenamate causes functional decoupling of glioblastoma cells.Figure 1. Meclofenamate causes functional decoupling of glioblastoma cells. (Schneider M, et al., 2021)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Highly recommend

GCaMP6f’s sensitivity is outstanding! Compared to other calcium indicators, this product provided clearer activity traces with minimal background noise.

Germany

06/05/2024

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction